Nektar Therapeutics
NKTR
NKTR
378 hedge funds and large institutions have $7.83B invested in Nektar Therapeutics in 2018 Q2 according to their latest regulatory filings, with 99 funds opening new positions, 128 increasing their positions, 128 reducing their positions, and 74 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.27% less ownership
Funds ownership: 6.51% → 6.24% (-0.27%)
53% less capital invested
Capital invested by funds: $16.7B → $7.83B (-$8.84B)
67% less funds holding in top 10
Funds holding in top 10: 18 → 6 (-12)
Holders
378
Holding in Top 10
6
Calls
$231M
Puts
$193M
Top Buyers
| 1 | +$257M | |
| 2 | +$124M | |
| 3 | +$79.4M | |
| 4 |
JP Morgan Chase
New York
|
+$67.1M |
| 5 |
O
OppenheimerFunds
New York
|
+$65M |
Top Sellers
| 1 | -$139M | |
| 2 | -$130M | |
| 3 | -$127M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$94.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$81.7M |